Arava(leflunomide)
Arava, Leflunomide (leflunomide) is a small molecule pharmaceutical. Leflunomide was first approved as Arava on 1998-09-10. It is used to treat rheumatic diseases and rheumatoid arthritis in the USA. It has been approved in Europe to treat psoriatic arthritis and rheumatoid arthritis. The pharmaceutical is active against dihydroorotate dehydrogenase (quinone), mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Arava, Leflunomide (discontinued: Leflunomide)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arava | New Drug Application | 2025-06-04 |
| inflatherm | ANDA | 2022-12-07 |
| lefluniclo | unapproved drug other | 2023-03-29 |
| leflunomide | ANDA | 2025-06-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
| rheumatic diseases | — | D012216 | M79.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
133 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | 9 | 24 | 21 | 17 | 70 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 8 | 22 | 18 | 14 | 62 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | 3 | — | 1 | 3 | 8 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | — | 1 | 2 | 3 | 7 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 2 | 1 | 1 | 1 | 4 |
| Immunoglobulin g4-related disease | D000077733 | — | D89.84 | — | — | — | 1 | 1 | 2 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 1 | 1 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | 1 | — | 1 | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Glomerulonephritis | D005921 | — | N05 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 2 | 1 | 1 | — | 1 | 4 |
| Nephritis | D009393 | — | N05 | — | 2 | 2 | — | 1 | 4 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | 2 | — | 1 | 3 |
| Virus diseases | D014777 | — | B34 | — | — | 1 | — | 1 | 2 |
| Central nervous system neoplasms | D016543 | — | — | — | 1 | 1 | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | — | 1 | 1 | — | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 1 | 2 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | — | 1 | — | — | 1 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | — | — | 1 | — | — | 1 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 4 | — | — | — | 5 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 4 | — | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 3 |
| Smoldering multiple myeloma | D000075122 | — | — | 1 | 2 | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | 2 | 1 | — | — | — | 2 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | 1 | — | — | 1 | 2 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | — | — | 1 | 2 |
| Viremia | D014766 | — | B34.9 | — | 1 | — | — | 1 | 2 |
| Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 2 |
| Syndrome | D013577 | — | — | 1 | 2 | — | — | — | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | — | — | — | — | 2 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 4 | 4 |
| Herpesviridae infections | D006566 | EFO_0007309 | B00.4 | — | — | — | — | 2 | 2 |
| Arteritis | D001167 | EFO_0009011 | I77.6 | — | — | — | — | 2 | 2 |
| Takayasu arteritis | D013625 | EFO_1001857 | M31.4 | — | — | — | — | 2 | 2 |
| Aortic arch syndromes | D001015 | — | — | — | — | — | — | 2 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Kidney transplantation | D016030 | — | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Leflunomide |
| INN | leflunomide |
| Description | Leflunomide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. It has a role as a non-steroidal anti-inflammatory drug, an antineoplastic agent, an antiparasitic agent, an EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor, a hepatotoxic agent, a prodrug, a pyrimidine synthesis inhibitor, an immunosuppressive agent, an EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor and a tyrosine kinase inhibitor. It is a monocarboxylic acid amide, a member of isoxazoles and a member of (trifluoromethyl)benzenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 75706-12-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL960 |
| ChEBI ID | 6402 |
| PubChem CID | 3899 |
| DrugBank | DB01097 |
| UNII ID | G162GK9U4W (ChemIDplus, GSRS) |
Target
Agency Approved
DHODH
DHODH
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Leflunomide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,463 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arava, Inflatherm, Lefluniclo, Leflunomide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
61,375 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use